Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. Viatris beat analysts’ revenue expectations by 1% last quarter ...

Viatris is one of the largest generic drug manufacturers in the world. Generic drugs make up about 40% of the firm's sales and, along with other generics manufacturers, they continues to suffer ...

The selloff in Viatris (VTRS) yesterday stopped when the stock found support Yjere is support around the $8.75 level because it had been support previously. Join Nic Chahine live on Wednesday ...

Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt ...

Zooming in further, Viatris has lagged behind the SPDR S&P Pharmaceuticals ETF’s 6.3% gains over the past 52 weeks and 4.8% return in 2025. On Nov. 7, Viatris announced its third-quarter ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...

Viatris Q4 sales fell 8% YoY to $3.52B, missing the $3.61B estimate, with adjusted EPS at $0.54 vs. $0.57 expected. 2025 revenue outlook cut due to FDA import alert, with a projected $500M impact ...

Despite operational successes, Viatris faced a significant 71% drop in GAAP net earnings due to international market pressures. Viatris delivered a mixed quarter, topping earnings expectations but ...